Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

计划入组 240 人 · 首次发布于 2021 年 3 月 12 日

Registry Study in MSI/dMMR Solid Tumors

计划入组 190 人 · 首次发布于 2023 年 8 月 22 日

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

计划入组 160 人 · 首次发布于 2025 年 12 月 3 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

BioLine Rx

Israel

Kura Oncology

United States

Crinetics

United States

Novartis' Oral WRN Helicase Inhibitor HRO761 Targets MSI-High and dMMR Tumors

Dostarlimab Shows Promise in Eliminating Need for Surgery Across Multiple dMMR Cancer Types

NGS Demonstrates High Concordance with IHC for MSI Assessment in Solid Tumors